Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Aktiespararna Småbolagsdagarna (June 2023)
19 slides from Expres2ion Biotech Holding Ab's conference presentation, Jun 13, 2023
Slide 1: Innovative vaccines for a healthier world
Click to edit Master title style Aktiespararna Småbolagsdagarna Innovative vaccines for a healthier world 13 June 2023 Hosted by STO:EXPRS2 Innovative Org. Nr. 559033-3729vaccines for a healthier world ExpreS ion Biotech Holding AB 2
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Investment Highlights
Investment Highlights High-potential vaccine pipeline focused on infectious diseases and oncology Core IP validated by late-stage clinical development and partners Global vaccine market continually growing, from USD 34bn (2017), USD 127bn (2021), to USD 202bn (2022) corresponding to 494% growth (201
Slide 4: Management team
Management team >150 years of life science experience Bent U. Frandsen, CEO Dr. Farshad Guirakhoo, CSO • MSc in Finance/Strategic Management, Copenhagen Business School, • PhD in Virology, Medical University of Vienna, Austria, and MSc in Denmark Genetics, International Institute for Biophysics and
Slide 5: Unique technology platforms
Unique technology platforms Combines a highly immunogenic antigen with unique presentation technology ExpreS2 platform Particle (VLP) technology - Combines S2 cells with patented - AdaptVac’s proprietary virus-like expression vectors (add a particles (VLP) technology securely specific gene into a ta
Slide 6: Pipeline
Pipeline Focus programs Pre-clinical Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Partner / funding COVID-19 ABNCoV2/SARS-CoV-2 cVLP BREAST CANCER ES2B-C001/Her2 cVLP 100% ExpreS2ion INFLUENZA MucoVax 50% / 50% CMV ES2B-I002 ExpreS2ion / Evaxion Exploratory Undi
Slide 7: Advancing towards key catalysts
Advancing towards key catalysts 2022 2023 2024 2025 ✓ ✓ BN Phase II trial BN Phase III trial BN Phase II 12-month durability data Expected royalties from sales COVID-19 readout H1 initiation Q3 ABNCoV2 BN Phase III initial readout BN initiating rolling submission BN ready for market launch (subject
Slide 8: End of quarter cash balances
FINANCE End of quarter cash balances SEK millions 180 168 Additional funds raised 160 • May 2023: SEK 54.5 million rights issue 150 142 139 140 125 120 111 Potential near-term non-dilutive cash 107 108 sources 100 83 • Warrants 80 72 • TO8 warrant subscription in September 2023 60 • ABNCoV2-related
Slide 9: ABNCoV2 – Next generation COVID-19 vaccine
CORONAVIRUS ABNCoV2 – Next generation COVID-19 vaccine Strong boosting effect across Durability across variants of concern variants of concern High level of protection – Stability at room temperature no need for adjuvant Similar increase in NAbs for Wuhan Next milestones: 12-month and Omicron durabi
Slide 10: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receives from Bavarian Nordic ExpreS2ion receives from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in develo
Slide 11: ES2B-C001: A new hope in breast cancer treatment
BREAST CANCER ES2B-C001 A new hope in breast cancer treatment Innovative vaccines for a healthier world 11
Slide 12: The current impact of breast cancer (BC)
BREAST CANCER The current impact of breast cancer (BC) Number of annual BC diagnoses (thousands) 2,300,000 new BC cases worldwide* HER2neg 685,000 300 >140k annual diagnoses** Annual diagnoses (thousands) deaths due to BC worldwide* HER2low 200 1 in 8 >400k annual diagnoses** Newly discovered subpop
Slide 13: Market opportunity and strategy
BREAST CANCER Market opportunity and strategy Total Addressable Market ~1.2 million patients treated /year for HER2+/low BC in 8MM €125 billion /year* Serviceable Available Market ~180k patients where ES2B-C001 can potentially act in EU Top5 + US €20 billion /year* Serviceable Obtainable Market ~37k
Slide 14: Current SoC in metastatic HER2+ BC
BREAST CANCER Current SoC in metastatic HER2+ BC LOT 1 LOT 2 LOT 3+ Non-targeted Endocrine therapies therapy* • Highly aggressive treatments Radiotherapy • Indiscriminate attack of healthy cells Chemotherapy HER2-targeted therapies Antibody Drug Conjugates • Severe side-effects Tyrosine kinase inhib
Slide 15: ES2B-C001 leverages protein expression and virus-like particles technology platforms
BREAST CANCER ES2B-C001 leverages protein expression and virus-like particles technology platforms HER2 protein Proven advantages of this approach Targets all 4 extra- cellular sub domains • Highly immunogenic using ExpreS2 protein expression platform • Attractive safety profile • Longevity of immun
Slide 16: Promising ES2B-C001 pre-clinical data
BREAST CANCER Promising ES2B-C001 pre-clinical data Effective inhibition of tumour growth 95% efficiency preventing tumour development ES2B-C001 Control + adjuvant Control ES2B-C001 ES2B-C001 + adjuvant Innovative vaccines for a healthier world Biomedicines (2022) Prevention and Therapy of Metastati
Slide 17: Promising ES2B-C001 pre-clinical data
BREAST CANCER Promising ES2B-C001 pre-clinical data Blocking of lung metastases In vitro effect in trastuzumab resistant cells Control ES2B-C001 ES2B-C001 + adjuvant Innovative vaccines for a healthier world Biomedicines (2022) Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Hum
Slide 18: Progression as Planned
BREAST CANCER Progression as Planned Important steps as ES2B-C001 is moving closer to the planned clinical Phase I trial in 2024 GMP Manufacturing Preclinical Safety GMP (Good Manufacturing Practice) Manufacturers selected and GLP (Good Laboratory Practice) CRO (Contract Research Work Order Stat
Slide 19: Thank you
Thank you investor@expres2ionbio.com Innovative vaccines for a healthier world 19
ExpreS2ion Biotech Holding — Aktiespararna Småbolagsdagarna (June 2023) on 6ix